Drugmaker Regeneron Pharmaceuticals will buy genetic testing firm 23andMe for $256 million through a bankruptcy auction, the companies said Monday.

Regeneron Pharmaceuticals will acquire ... Read next BI Tech Memo An icon in the shape of an angle pointing down.

(Reuters) -The founder of 23andMe, Anne Wojcicki, has asked a U.S. judge to reopen an auction for the genetic testing company ...

( NewsNation) — The interim CEO of 23andMe will face questions from lawmakers Wednesday about the DNA company’s data privacy amid a multistate lawsuit about its customers’ genetic data. The Senate ...

Regeneron is willing to make a new bid for 23andMe's assets, but wants a $10 million breakup fee if Wojcicki’s bid is ...

Biotechnology company Regeneron Pharmaceuticals is buying 23andMe for $256 million, two months after the genetic testing company filed for Chapter 11 bankruptcy protection. In March 23andMe said ...

Genetic testing firm 23andMe is set to be acquired by drug company Regeneron Pharmaceuticals following its bankruptcy in March, the companies announced on Monday, May 19. Regeneron purchased the ...

Drugmaker Regeneron Pharmaceuticals, Inc. (REGN) said on Monday that it will acquire the assets of bankrupt biotechnology company 23andMe Holding Co. for $256 million. Regeneron intends to acquire ...

Drugmaker Regeneron Pharmaceuticals will buy genetic testing firm 23andMe for $256 million through a bankruptcy auction, the companies said Monday. Regeneron said it will comply with 23andMe’s ...